Rapid multiplex molecular syndromic panels (RMMSP) (3 or more pathogens and time-to-results < 6 h) allow simultaneous detection of multiple pathogens and genotypic resistance markers. Their implementation has revolutionized the clinical landscape by significantly enhancing diagnostic accuracy and reducing time-to-results in different critical conditions. The current revision is a comprehensive but not systematic review of the literature. We conducted electronic searches of the PubMed, Medline, Embase, and Google Scholar databases to identify studies assessing the clinical performance of RMMSP in critically ill patients until July 30, 2024. A multidisciplinary group of 11 Spanish specialists developed clinical questions pertaining to the indications and limitations of these diagnostic tools in daily practice in different clinical scenarios. The topics covered included pneumonia, sepsis/septic shock, candidemia, meningitis/encephalitis, and off-label uses of these RMMSP. These tools reduced the time-to-diagnosis (and therefore the time-to-appropriate treatment), reduced inappropriate empiric treatment and the length of antibiotic therapy (which has a positive impact on antimicrobial stewardship and might be associated with lower in-hospital mortality), may reduce the length of hospital stay, which could potentially lead to cost savings. Despite their advantages, these RMMSP have limitations that should be known, including limited availability, missed diagnoses if the causative agent or resistance determinants are not included in the panel, false positives, and codetections. Overall, the implementation of RMMSP represents a significant advancement in infectious disease diagnostics, enabling more precise and timely interventions. This document addresses relevant issues related to the use of RMMSP on different critically ill patient profiles, to standardize procedures, assist in making management decisions and help specialists to obtain optimal outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1186/s13054-024-05224-3 | DOI Listing |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11687037 | PMC |
Biosens Bioelectron
December 2024
Biomedical Engineering, School of Medicine, The Chinese University of Hong Kong, Shenzhen, 518172, China; Juxintang (Chengdu) Biotechnology Co., Ltd., Chengdu, 641400, China. Electronic address:
This review examines the potential of aggregation-induced luminescence (AIE) materials in lateral flow assays (LFA) to enhance the sensitivity and specificity of a range of assay applications. LFA is a straightforward and effective paper-based platform for the rapid detection of target analytes in mixtures. Its simple design, low cost, and ease of operation are among the most attractive advantages of LFA.
View Article and Find Full Text PDFmSphere
December 2024
Department of Microbiology and Immunology, School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
particularly the group, is a major cause of nosocomial infections, and carbapenem-resistant spp. are important human pathogens. We collected 492 spp.
View Article and Find Full Text PDFAnal Chem
January 2025
SB BIOSCIENCE Inc., Room 120, Venture Building, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea.
The need for accurate and simultaneous diagnosis of multiple respiratory infectious diseases has become increasingly critical due to ongoing viral mutations and the similarity of symptoms among various viruses. Here, we have advanced our detection capabilities by developing a multiplex lateral flow immunoassay (LFA) platform that integrates oligonucleotides and antibodies, enabling the simultaneous detection of five respiratory viruses: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Influenza A (FluA), Influenza B (FluB), Respiratory syncytial virus (RSV), and Adenovirus (ADV), on a single membrane. By applying the oligonucleotide and antibody-conjugated AuNPs, the platform enables highly sensitive and specific detection.
View Article and Find Full Text PDFMikrobiyol Bul
October 2024
University of Health Sciences, Dr. Behçet Uz Pediatric Diseases and Surgery Training and Research Hospital, Clinic of Pediatric Infectious Diseases, İzmir, Türkiye.
Central nervous system infections (CNS) are life-threatening infections in children, requiring urgent intervention and rapid diagnosis. In this study, we aimed to investigate the efficacy of syndromic tests in diagnosing CNS infections and the distribution of viral pathogens in pediatric patients. A total of 145 pediatric patients with a prediagnosis of CNS infection based on clinical findings by a pediatric infectious disease specialist were included in the study.
View Article and Find Full Text PDFSmall
January 2025
Biomedical Nanosensors, Fraunhofer Institute for Microelectronic Circuits and Systems Finkenstrasse 61, 47057, Duisburg, Germany.
Sepsis is a global health challenge, characterized by a dysregulated immune response, leading to organ dysfunction and death. Despite advances in medical care, sepsis continues to claim a significant toll on human lives, with mortality rates from 10-25% for sepsis and 30-50% for septic shock, making it a leading cause of death worldwide. Current diagnostic methods rely on clinical signs, laboratory parameters, or microbial cultures and suffer from delays and inaccuracies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!